Trials / Recruiting
RecruitingNCT07438782
First Time in Human (FTIH) Study to Investigate the Safety and Preliminary Activity of GSK5533524 Alone or in Combination in Adult Participants With Advanced Solid Tumors
A Phase 1, Open-label, Multicenter Study of GSK5533524 Alone or in Combination With Other Anti-cancer Agents, in Adult Participants With Selected Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 97 (estimated)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate a new drug GSK5533524 in adults with certain advanced cancers to find a safe dose and learn how well people tolerate it, so researchers can choose the best dose for the next stage of testing. The study will also check whether the drug can shrink tumours or slow cancer growth, monitor how the body absorbs and breaks down the drug, and look for any immune reactions that the body might develop against the treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GSK5533524 | GSK5533524 will be administered. |
Timeline
- Start date
- 2026-03-23
- Primary completion
- 2029-02-13
- Completion
- 2029-02-13
- First posted
- 2026-02-27
- Last updated
- 2026-04-06
Locations
2 sites across 2 countries: Canada, Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07438782. Inclusion in this directory is not an endorsement.